Kyrgyzstan Medical Device Adverse Event Reporting and Vigilance: Statutory Definitions, Duties and Practical Alignment

1. Key takeaways

Kyrgyzstan requires the reporting of adverse events involving medical devices. The obligated party is the manufacturer or its authorized representative, and the governing procedure is Annex 2 to Cabinet Resolution No. 513, the Procedure for Monitoring the Safety, Quality and Effectiveness of Medical Devices. Law No. 216 provides a statutory definition of adverse events, covering device defects, deterioration of characteristics or performance, insufficient or incorrect accompanying information, and side effects not listed in the instructions for use, where the event has caused or may cause death or a serious deterioration in health. This article sets out only verifiable structural conclusions; specific reporting deadlines must be confirmed against the original text of Annex 2.

2. Legal basis

1. Cabinet Resolution No. 513, August 27, 2024, Annex 2: the Procedure for Monitoring the Safety, Quality and Effectiveness of Medical Devices.
2. Article 14 of Law No. 216: the obligation to report changes in device data and information rests with the manufacturer or its authorized representative.
3. Article 15 of Law No. 216: grounds for suspension and revocation of registration certificates.
4. Article 3 of Law No. 216: statutory definition of an adverse event — any defect in a device and/or deterioration of its characteristics or performance, or insufficiency or incorrectness of accompanying information (documentation), or a side effect not listed in the instructions for use, which directly or indirectly led or may lead to death or a serious deterioration in the health of a user or a third party.
5. Article 3 of Law No. 216 (definitions): serious deterioration in health includes a life-threatening illness, permanent impairment of a body function or irreversible damage to a body structure, fetal abnormality, fetal death, congenital abnormality or birth injury, a condition requiring medical or surgical intervention, and a condition requiring hospitalization or significant prolongation of an existing hospitalization.

Source note: the specific deadlines, forms and reporting channels for adverse event reporting were not available this round in official wording suitable for verbatim citation. This article therefore does not state a specific number of days; the original text of Annex 2 to Cabinet Resolution No. 513 prevails.

3. Expert insights

Insight one: the statutory phrase or may lead sets the reporting threshold at risk, not at materialized harm.

The definition of an adverse event in Law No. 216 uses the wording led or may lead to death or a serious deterioration in health. This means that the mere possibility of a serious outcome brings the situation within the reporting scope, without waiting for actual harm to occur. This is consistent with international practice, but it places higher demands on a company’s internal information-gathering capability — front-line staff must be able to recognize situations that have not yet caused harm but could do so.

Insight two: the definition covers three categories of events, and insufficient or incorrect information is the most frequently missed.

The definition lists three categories: first, device defects or deterioration of characteristics or performance; second, insufficient or incorrect accompanying information (documentation); third, side effects not listed in the instructions for use. The second category is the easiest to overlook — labeling errors, inaccurate translation of instructions for use, and missing warnings all constitute insufficient or incorrect accompanying information and are therefore adverse events in their own right. This echoes the emphasis on labeling consistency in article 30 of this series.

Insight three: serious deterioration in health has a statutory checklist that can be used as a decision tool.

The law enumerates the situations: life-threatening illness, permanent impairment of body functions, irreversible damage to body structures, fetal abnormality, fetal death, congenital abnormality or birth injury, the need for medical or surgical intervention, and the need for hospitalization or significant prolongation of hospitalization. This list can be converted directly into a decision table for front-line staff to compare case by case, reducing the variability of subjective judgment.

Insight four: the obligated party is the manufacturer or its authorized representative, but the raw information originates in the distribution channel and healthcare facilities.

Article 14 places the obligation on the manufacturer or its authorized representative, yet first-hand event information comes from distributors, hospitals and users. Companies must therefore build an information loop that flows back from the channel: distributor → authorized representative → manufacturer → competent authority. If any link in this chain breaks, events go unreported (see article 39 of this series on distributor files).

Insight five: the consequence of under-reporting can point back at the registration certificate itself.

Article 15 lists the emergence of new systematic data indicating that risks outweigh benefits as a ground for revocation. If adverse events go unreported for a long period and the regulator learns of them through other channels, this provision may be triggered. Timely and complete reporting is thus itself a form of protection for the registration certificate.

4. Practical recommendations

First, convert the statutory definition into a decision table for front-line use. We recommend building a decision table based on the three event categories crossed with the seven forms of serious deterioration, for use by distributors and clinical support staff, to reduce the probability of missed reports.

Second, build an information loop that flows back from the channel. We recommend specifying in distribution agreements and channel training how adverse events are identified, recorded and escalated, and designating contact persons on both sides.

Third, agree on reporting responsibilities and response deadlines in agreements. We recommend stipulating that the authorized representative is responsible for translation, submission and follow-up; the manufacturer is responsible for technical assessment and content; and that the parties agree on internal response deadlines.

Fourth, bring accompanying-information events within the surveillance scope. We recommend adding a checkpoint to change management for labels and instructions for use: if an error is found in the labeling of a marketed product, assess whether it constitutes a reportable adverse event.

Fifth, once the original text of Annex 2 is obtained, verify reporting deadlines and forms. We recommend asking the authorized representative to request the current requirements from the competent authority and updating internal workflows accordingly (this article does not state a specific number of days).

5. Verification checklist

• □ An adverse event decision table based on the three event categories crossed with the seven forms of serious deterioration has been prepared and distributed to front-line staff;
• □ An information loop from distributor to authorized representative to manufacturer to competent authority has been established, with contact persons designated on both sides;
• □ Agreements specify reporting responsibilities (authorized representative for translation and submission, manufacturer for technical assessment) and internal response deadlines;
• □ Change management for labels and instructions for use includes a checkpoint on whether accompanying information constitutes a reportable adverse event;
• □ The original text of Annex 2 to Cabinet Resolution No. 513 has been obtained to verify reporting deadlines and forms;
• □ Adverse event records are included in the standing inspection readiness package and kept up to date.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system conformity support, post-market surveillance and vigilance system setup, import and distribution compliance, and fee calculation and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations and has built stable local cooperation networks in Bishkek, Almaty, Tashkent and Moscow. Working in Chinese, Russian and English, we deliver actionable solutions for foreign manufacturers on the key issues commonly encountered in CIS markets, including authorized representative arrangements, notarization and legalization chains for powers of attorney, localization of technical documentation, and inspection readiness.

We hold to one principle: every regulatory conclusion we publish must be traceable to verifiable official sources; figures and timelines that cannot be verified are always marked as practical estimates and are never presented as legal requirements drawn from experience.

GRZAN provides registration and compliance support in this country for manufacturers, importers and authorized representatives. For project inquiries on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Regulatory Registration and Compliance Services for Medical Devices